Plaque Psoriasis

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

In a session presented at the SDPA Fall Conference, Karan Lal, DO, spoke on the topic of GLP-1 agonist drugs for weight loss and their connection to dermatology.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

In this review of the month of October, HCPLive highlights some of the most significant dermatology news updates.

These phase 4 data from the UnlIMMited trial highlight the efficacy and safety of risankizumab for psoriasis in the genital or scalp region.

Song interviewed with the team regarding his session, discussing recent data on IL-23 inhibition in patients with psoriasis.

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

Panelists discuss how the head-to-head ICONIC-ADVANCE studies demonstrated icotrokinra’s superior efficacy vs deucravacitinib, with approximately double the complete clearance rates and a safety profile similar to placebo.

Panelists discuss how icotrokinra represents a novel oral peptide that selectively blocks the IL-23 receptor, offering the trusted safety profile of IL-23 inhibition in an oral formulation with high selectivity and no off-target effects.

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

Panelists discuss how second-generation PDE4 inhibitors, such as orismilast, aim to improve upon apremilast’s efficacy while maintaining safety, with phase 2 data showing PASI 75 rates up to 50%.

Panelists discuss how emerging TYK2 inhibitors such as brepocitinib and ESK001 target the JAK/STAT pathway to block IL-23 and IL-17 signaling, showing promising phase 2 results with PASI 100 rates around 33% and PASI 75 rates of 64%.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.

Panelists discuss how effective shared decision-making involves clinicians presenting 2 to 3 optimal treatment options based on patient-specific factors rather than overwhelming patients with all possibilities or making unilateral decisions, ultimately improving treatment adherence.

Panelists discuss how many eligible patients with psoriasis remain undertreated despite advanced therapy availability due to patient discontinuation from topical burden, injection anxiety, and the historical lack of effective oral options with good safety profiles.

In this analysis, investigators highlight the impact of the route of MTX administration on drug survival among patients with psoriasis.

These data highlight secukinumab’s potential as a treatment to provide enhanced psychological outcomes among those with psoriasis.

This study highlighted tildrakizumab’s use in daily practice within a heterogeneous cohort of patients with psoriasis commonly affected by comorbid conditions.

Panelists discuss how modern topical treatments have evolved beyond traditional corticosteroids to include more effective nonsteroidal options, such as tapinarof and roflumilast, which provide better long-term control and can complement systemic therapies.